The effects of edaravone in ketamine-induced model of mania in rats.
Bipolar disorder is a chronic disease characterized by recurring episodes of mania and depression that can lead to disability. This study investigates the protective effects of edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one), a drug with well-known antioxidant properties, in a model of mania induced by ketamine in rats. Locomotor activity was assessed in the open-field test. Superoxide dismutase (SOD), catalase (CAT) and thiobarbituric acid reactive substances (TBARS) levels were measured in order to evaluate oxidative damage in the rat hippocampus and prefrontal cortex. Increased locomotor activity (hyperlocomotion) was observed at the open-field test with ketamine treatment (25 mg/kg, i.p., 8 days). Edaravone (18 mg/kg) treatment did not prevent hyperlocomotion in the mania model induced with ketamine in rats, but lithium chloride (47.5 mg/kg, i.p., positive control) did prevent hyperlocomotion. Edaravone and lithium chloride treatments were found to reduce the increase in SOD and CAT activity following ketamine administration in a non-significant manner but caused no change in TBARS levels.
Department of Psychiatry, School of Medicine, Karadeniz Technical University, Trabzon, Turkey. filiz_civil@yahoo.com.
Filiz Civil
FC
Arslan
Department of Psychiatry, School of Medicine, Karadeniz Technical University, Trabzon, Turkey.
Ahmet
A
Tiryaki
Department of Medical Physiology, Faculty of Medicine, Health Sciences University, Istanbul, Turkey.
Mehmet
M
Yıldırım
Department of Psychiatry, School of Medicine, Karadeniz Technical University, Trabzon, Turkey.
Evrim
E
Özkorumak
Department of Biochemistry, School of Medicine, Karadeniz Technical University, Trabzon, Turkey.
Ahmet
A
Alver
Department of Psychiatry, School of Medicine, Karadeniz Technical University, Trabzon, Turkey.
İlkay Keleş
İK
Altun
Department of Biochemistry, School of Medicine, Karadeniz Technical University, Trabzon, Turkey.
İmran
İ
İnce
Department of Physiology, School of Medicine, Karadeniz Technical University, Trabzon, Turkey.
Öznur
Ö
Gedikli
D000704:Analysis of Variance; D000818:Animals; D018692:Antimanic Agents / Q000627:therapeutic use; D000983:Antipyrine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D001714:Bipolar Disorder / Q000139:chemically induced / Q000188:drug therapy* / Q000473:pathology; D001921:Brain / Q000187:drug effects / Q000378:metabolism; D002374:Catalase / Q000378:metabolism; D004195:Disease Models, Animal; D004334:Drug Administration Schedule; D000077553:Edaravone; D018691:Excitatory Amino Acid Antagonists / Q000633:toxicity; D005106:Exploratory Behavior / Q000187:drug effects; D005260:Female; D007649:Ketamine / Q000633:toxicity; D018021:Lithium Chloride / Q000627:therapeutic use; D008124:Locomotion / Q000187:drug effects; D008315:Malondialdehyde / Q000378:metabolism; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D051381:Rats; D017207:Rats, Sprague-Dawley; D013482:Superoxide Dismutase / Q000378:metabolism
D018692:Antimanic Agents; D018691:Excitatory Amino Acid Antagonists; D018696:Neuroprotective Agents; D008315:Malondialdehyde; D007649:Ketamine; D002374:Catalase; D013482:Superoxide Dismutase; D018021:Lithium Chloride; D000077553:Edaravone; D000983:Antipyrine